摘要
目的:探讨在正常和异常CA125水平的卵巢癌患者血清和尿液MMP-2水平的变化。方法:选取83例卵巢癌患者(CA125正常的卵巢癌患者38例,CA125异常的卵巢癌患者45例),50例健康体检妇女为研究对象。用ELISA方法测定血清和尿液中MMP-2的水平。结果:CA125正常和异常的卵巢癌组血清和尿液中MMP-2水平明显高于对照组(P<0.01)。血清MMP-2和尿液MMP-2诊断卵巢癌的ROC曲线下面积分别为0.846和0.860(P<0.01);血清MMP-2和尿液MMP-2在CA125正常情况下诊断卵巢癌的ROC曲线下面积分别为0.814和0.853(P<0.01)。尿液MMP-2和CA125的联合诊断达到最高灵敏度96.7%和特异度92.5%。结论:血清与尿液中MMP-2的检测可以用于卵巢癌的辅助诊断。
Objective：To evaluate serum and urine matrix metalloproteinase-2（MMP-2） in patients with normal or abnormal CA125 level for diagnosis of ovarian cancer.Methods：A total of 83 patients with ovarian cancer（38 patients with normal CA125 level,45 patients with abnormal CA125 level）,and 50 healthy controls were recruited in this study.Serum and urine levels of MMP-2 were measured by ELISA methods.Results：Serum and urine levels of MMP-2 in ovarian cancer patients with normal or abnormal CA125 level were higher significantly than those in healthy controls（P0.01）.Receiver operating characteristic（ROC） curves of serum and urine MMP-2 for diagnosis of ovarian cancer were 0.846 and 0.860,respectively.ROC curves of serum and urine MMP-2 in patients with normal CA125 level for diagnosis of ovarian cancer were 0.814 and 0.853,respectively.The combined detection of urine MMP-2 and CA125 reached the highest sensitivity of 96.7% and specificity of 92.5%.Conclusion：Serum and urine MMP-2 may represent the helpful adjunct to conventional diagnostic tools in ovarian cancer.
出处
《现代肿瘤医学》
CAS
2012年第10期2148-2150,共3页
Journal of Modern Oncology
基金
辽宁省科技厅自然科学基金项目资助(编号:201102257)
